Error message
The text size have not been saved, because your browser do not accept cookies.
Executive summary
| Target not reached or not in line with other registries |
| Target attained |
| Indicator | UKIACR average (population) | UKIACR average (country) | England | Scotland | Wales | Northern Ireland | Republic of Ireland |
|---|
| Stability: Percentage change (%) for all cancers (C00-C97 ex. C44) in 2015 compared with 2012-2014 | 1.0% | 0.4% | 1.3% | -1.9% | -1.7% | 1.6% | 2.4% |
| Registry Creep: Percentage (%) for all cancers (C00-C97 ex. C44) of 2014 registrations at 31/01/2017 compared with registrations at 31/01/2016 | 1.3% | 2.3% | 1.0% | 2.5% | 2.6% | 2.5% | 2.7% |
| Staging: Proportion (%) of all cases (C00-C97 ex. C44) with valid known stage registered out of all 2015 registered cancers (C00-C97 ex. C44) | 76.8% | 69.4% | 80.4% | 60.8% | 65.1% | 82.4% | 58.1% |
| Average of Core Patient Information Complete: Average percentage (%) of all cancers (C00-C97 ex. C44) registered with demographic information | 98.2% | 97.1% | 98.9% | 96.0% | 91.0% | 100.0% | 99.6% |
| Average of Core Tumour Information Complete: Average percentage (%) of all cancers (C00-C97 ex. C44) registered with tumour information | 97.2% | 96.4% | 97.5% | 96.4% | 94.3% | 96.8% | 97.2% |
| Diagnosing Hospital Known: Percentage (%) of all cancers (C00-C97 ex. C44) registered with an organisation of diagnosis | 97.4% | 96.1% | 97.9% | 93.2% | 98.3% | 95.5% | 95.8% |
| Death Certificate Only (DCO) Rates: Percentage (%) of all cancers (C00-C97 ex. C44) registered as a DCO | 0.7% | 0.9% | 0.7% | 0.4% | 1.7% | 0.5% | 1.0% |
| Zero Day Survivors: Percentage (%) of all cancers (C00-C97 ex. C44) registered with the date of death equals the date of diagnosis | 1.4% | 1.3% | 1.5% | 0.8% | 2.2% | 0.6% | 1.6% |
| Microscopically Verified: Percentage (%) of all cancers (C00-C97 ex. C44) that are microscopically verified | 85.4% | 85.8% | 85.4% | 84.2% | 80.4% | 86.7% | 92.1% |
| Non Specific Codes: Percentage (%) of all cancers (C00-C97 ex. C44) that are microscopically verified with non specific morphology codes | 2.0% | 3.7% | 1.5% | 1.5% | 11.0% | 1.5% | 2.8% |
| Grade: Percentage (%) of all cancers (C00-C97 ex. C44) registered with a known grade | 58.9% | 55.1% | 60.3% | 58.5% | 40.3% | 61.0% | 55.2% |
| Treatment: Percentage (%) of all cancers (C00-C97 ex. C44) registered with any treatment | 83.3% | 74.0% | 87.5% | 69.8% | 57.3% | 90.6% | 64.8% |
| Breast Screening Data: Percentage of breast cancer (C50) cases from 2014 screen detected for ages 50-64 | 48.0% | 50.7% | 47.1% | 48.1% | 51.5% | 51.4% | 55.2% |
| Cervical Screening Data: Percentage of cervical cancer (C53) cases from 2014 screen detected for ages 25-60 | 19.2% | 30.0% | 13.8% | 54.4% | NA | 21.9% | NA |
| Bowel Screening Data: Percentage of bowel cancer (C18-C20) cases from 2014 screen detected for ages 60-69 | 18.8% | 23.7% | 17.0% | 29.7% | 21.2% | 26.9% | NA |
Registrations and timeliness
|
UKIACR average (population) |
UKIACR average (country) |
England |
Scotland |
Wales |
Northern Ireland |
Republic of Ireland |
| 2012 |
368966 |
73793 |
289371 |
31440 |
18451 |
9046 |
20658 |
| 2013 |
380497 |
76099 |
298808 |
31919 |
19690 |
9114 |
20966 |
| 2014 |
382412 |
76482 |
299847 |
32337 |
19839 |
9168 |
21221 |
| 2014 (from Previous PI) |
377260 |
75452 |
296815 |
31541 |
19325 |
8936 |
20643 |
| No. of 2015 not-finalised cases |
358 |
72 |
336 |
22 |
0 |
0 |
0 |
| No. of 2015 full cases |
380964 |
76193 |
299969 |
31277 |
19004 |
9256 |
21458 |
| Registry creep |
1.3% |
2.3% |
1.0% |
2.5% |
2.6% |
2.5% |
2.7% |
| Not-finalised cases |
0.1% |
0.0% |
0.1% |
0.1% |
0.0% |
0.0% |
0.0% |
No. of Cases (current year) and percentage change vs. previous year (persons)
|
UKIACR average (population) |
UKIACR average (country) |
England |
Scotland |
Wales |
Northern Ireland |
Republic of Ireland |
| All invasive xnmsc |
380,964 (1%) |
0.4% |
299969 (1.3%) |
31277 (-1.9%) |
19004 (-1.7%) |
9256 (1.6%) |
21458 (2.4%) |
| All xnmsc 0-24 |
4,336 (3.3%) |
2.9% |
3417 (3.6%) |
310 (6.7%) |
205 (4.8%) |
118 (5%) |
286 (-5.5%) |
| All xnmsc 25-59 |
90,238 (1.8%) |
0.6% |
70178 (2.4%) |
7346 (-2%) |
4003 (-0.6%) |
2364 (0.8%) |
6347 (2.5%) |
| All xnmsc 60-79 |
203,814 (1.6%) |
0.6% |
159767 (2.1%) |
17103 (-1.9%) |
10521 (-2%) |
4945 (1.8%) |
11478 (2.8%) |
| All xnmsc 80+ |
82,576 (-1.5%) |
-0.5% |
66607 (-1.6%) |
6518 (-2.3%) |
4275 (-2.2%) |
1829 (1.9%) |
3347 (1.7%) |
| All registrations |
632,493 (2.7%) |
1.0% |
493618 (3.4%) |
52385 (-0.5%) |
28808 (-1.7%) |
17248 (0.4%) |
40434 (3.6%) |
| Haematology |
33,437 (1.3%) |
2.0% |
26871 (1.2%) |
2371 (0.3%) |
1704 (4%) |
775 (3.7%) |
1716 (0.8%) |
| Head and Neck |
12,752 (5%) |
5.9% |
9733 (5.4%) |
1280 (-0.6%) |
685 (4.3%) |
362 (12.2%) |
692 (8.4%) |
| Lower GI |
47,669 (0.3%) |
-2.6% |
37324 (1.2%) |
3928 (-4%) |
2408 (-5.9%) |
1189 (-9%) |
2820 (4.7%) |
| Upper GI |
16,947 (0.4%) |
-1.2% |
13110 (1.1%) |
1526 (-6.6%) |
895 (0.9%) |
404 (-7%) |
1012 (5.7%) |
| HPB |
18,816 (3.1%) |
3.9% |
14748 (3.1%) |
1620 (1.8%) |
968 (3.9%) |
491 (9.5%) |
989 (1.4%) |
| Trachea, Bronchus & Lung |
48,723 (-0.6%) |
-1.4% |
37641 (0.3%) |
4968 (-7.2%) |
2448 (-0.7%) |
1240 (0.8%) |
2426 (-0.5%) |
| Melanoma |
17,071 (8.9%) |
9.9% |
13356 (8.4%) |
1358 (12.6%) |
784 (0.5%) |
402 (11.6%) |
1171 (16.5%) |
| Breast |
58,476 (2.8%) |
4.5% |
46100 (2.5%) |
4753 (1.8%) |
2836 (1%) |
1468 (11.4%) |
3319 (5.8%) |
| Cervix |
3,366 (-3.3%) |
-5.9% |
2521 (-3.3%) |
379 (12.6%) |
150 (-10%) |
81 (-13.5%) |
235 (-15.4%) |
| Other Female Genitals |
18,946 (-1.5%) |
-2.1% |
14940 (-1.2%) |
1574 (-1%) |
948 (-10.3%) |
506 (0%) |
978 (1.8%) |
| Prostate |
50,239 (0.1%) |
-1.5% |
40310 (1.1%) |
3052 (-6.2%) |
2567 (-0.9%) |
1133 (4.4%) |
3177 (-5.9%) |
| Kidney |
12,759 (2.9%) |
-0.7% |
10333 (4.3%) |
924 (0.2%) |
547 (-8.5%) |
339 (6.7%) |
616 (-6.3%) |
| Bladder |
10,582 (-3%) |
1.0% |
8499 (-4%) |
822 (-1.6%) |
554 (-4.9%) |
213 (1.9%) |
494 (13.4%) |
| Brain and CNS |
5,858 (1.2%) |
-4.2% |
4652 (3.2%) |
412 (-9.2%) |
278 (-4.9%) |
137 (-8.5%) |
379 (-1.6%) |
| Thyroid & other endocrine glands |
4,138 (5.5%) |
-2.4% |
3343 (8.2%) |
300 (4.9%) |
125 (-10.7%) |
87 (-4.4%) |
283 (-10.2%) |
| CUP |
9,132 (-5.3%) |
-1.8% |
7104 (-7%) |
865 (0%) |
524 (-4.6%) |
163 (-19.3%) |
476 (22.1%) |
| Other invasive cancer |
12,053 (-2.4%) |
-1.2% |
9384 (-3.1%) |
1145 (-1.1%) |
583 (-6.4%) |
266 (-7.1%) |
675 (11.4%) |
| Breast in situ |
8,342 (9.4%) |
14.2% |
6852 (9.6%) |
466 (4.6%) |
336 (-7%) |
237 (54.9%) |
451 (8.8%) |
| Cervix in situ |
33,608 (-1.7%) |
-2.6% |
25034 (-1.5%) |
2542 (-3%) |
1734 (-15.4%) |
1145 (-0.4%) |
3153 (7.1%) |
| Other tumours |
53,714 (-0.3%) |
-0.8% |
36536 (0.1%) |
6236 (-3.4%) |
3333 (7%) |
2780 (-10.3%) |
4829 (2.6%) |
| Other non-melanoma skin cancer |
2371 (4.4%) |
8.2% |
1460 (-2.2%) |
178 (18.9%) |
481 (57.4%) |
61 (-66%) |
191 (32.9%) |
| Basal cell carcinoma |
116078 (8.6%) |
3.6% |
95562 (9.8%) |
8474 (5.6%) |
2145 (-10.6%) |
2715 (7.9%) |
7182 (5.1%) |
| Squamous cell carcinoma |
37500 (11.4%) |
7.1% |
28205 (13.4%) |
3296 (8.1%) |
1775 (2.1%) |
1054 (7.6%) |
3170 (4.3%) |
Percentage (%) of death certificate only cases (persons) for 2015
|
UKIACR average (population) |
UKIACR average (country) |
England |
Scotland |
Wales |
Northern Ireland |
Republic of Ireland |
| All invasive xnmsc |
0.7% |
0.9% |
0.7% |
0.4% |
1.7% |
0.5% |
1.0% |
| All xnmsc 0-24 |
0.1% |
0.2% |
0.1% |
0.0% |
0.0% |
0.0% |
0.7% |
| All xnmsc 25-59 |
0.1% |
0.1% |
0.1% |
0.1% |
0.3% |
0.1% |
0.1% |
| All xnmsc 60-79 |
0.4% |
0.5% |
0.3% |
0.3% |
1.0% |
0.4% |
0.7% |
| All xnmsc 80+ |
2.3% |
2.7% |
2.2% |
0.9% |
5.0% |
1.2% |
4.0% |
| All registrations |
0.5% |
0.6% |
0.5% |
0.2% |
1.3% |
0.3% |
0.6% |
| Haematology |
0.9% |
0.8% |
0.9% |
0.1% |
1.9% |
0.1% |
0.9% |
| Head and Neck |
0.3% |
0.3% |
0.3% |
0.0% |
1.0% |
0.0% |
0.3% |
| Lower GI |
0.5% |
0.7% |
0.5% |
0.4% |
1.1% |
0.5% |
1.1% |
| Upper GI |
0.7% |
1.1% |
0.6% |
0.5% |
1.9% |
0.5% |
1.9% |
| HPB |
1.3% |
1.7% |
1.2% |
0.6% |
3.1% |
1.2% |
2.5% |
| Trachea, Bronchus & Lung |
0.7% |
1.0% |
0.6% |
0.4% |
1.9% |
0.7% |
1.5% |
| Melanoma |
0.1% |
0.0% |
0.1% |
0.0% |
0.0% |
0.0% |
0.0% |
| Breast |
0.3% |
0.3% |
0.3% |
0.1% |
0.7% |
0.1% |
0.1% |
| Cervix |
0.2% |
0.4% |
0.2% |
0.5% |
0.0% |
1.2% |
0.0% |
| Other Female Genitals |
0.6% |
0.7% |
0.6% |
0.3% |
1.4% |
0.2% |
1.1% |
| Prostate |
0.5% |
0.4% |
0.5% |
0.2% |
0.9% |
0.1% |
0.4% |
| Kidney |
0.7% |
0.8% |
0.6% |
0.4% |
1.3% |
0.0% |
1.8% |
| Bladder |
0.9% |
0.7% |
0.9% |
0.1% |
1.3% |
0.0% |
1.0% |
| Brain and CNS |
0.9% |
0.9% |
0.8% |
0.5% |
1.1% |
0.0% |
2.1% |
| Thyroid & other endocrine glands |
0.3% |
0.5% |
0.3% |
0.0% |
0.8% |
1.1% |
0.4% |
| CUP |
5.2% |
6.2% |
5.0% |
2.7% |
12.4% |
4.9% |
5.9% |
| Other invasive cancer |
1.4% |
2.3% |
1.1% |
1.2% |
4.5% |
2.6% |
2.2% |
| Breast in situ |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
| Cervix in situ |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
| Other tumours |
0.6% |
0.4% |
0.8% |
0.1% |
1.1% |
0.0% |
0.0% |
Percentage (%) of zero survival cases (persons)
|
UKIACR average (population) |
UKIACR average (country) |
England |
Scotland |
Wales |
Northern Ireland |
Republic of Ireland |
| All invasive xnmsc |
1.4% |
1.3% |
1.5% |
0.8% |
2.2% |
0.6% |
1.6% |
| All xnmsc 0-24 |
0.3% |
0.3% |
0.3% |
0.3% |
0.0% |
0.0% |
1.0% |
| All xnmsc 25-59 |
0.3% |
0.3% |
0.4% |
0.2% |
0.4% |
0.2% |
0.3% |
| All xnmsc 60-79 |
1.0% |
0.9% |
1.0% |
0.7% |
1.3% |
0.6% |
1.1% |
| All xnmsc 80+ |
3.9% |
3.8% |
3.9% |
1.7% |
6.0% |
1.4% |
6.0% |
| All registrations |
1.0% |
0.9% |
1.0% |
0.5% |
1.6% |
0.3% |
0.9% |
| Haematology |
1.6% |
1.5% |
1.7% |
0.4% |
2.8% |
0.6% |
1.7% |
| Head and Neck |
0.5% |
0.5% |
0.5% |
0.0% |
1.2% |
0.0% |
0.7% |
| Lower GI |
1.3% |
1.2% |
1.4% |
0.7% |
1.5% |
0.6% |
1.8% |
| Upper GI |
1.7% |
1.5% |
1.7% |
0.8% |
2.5% |
0.5% |
2.1% |
| HPB |
2.9% |
2.7% |
3.0% |
1.4% |
3.8% |
1.0% |
4.0% |
| Trachea, Bronchus & Lung |
2.1% |
1.9% |
2.3% |
1.1% |
2.7% |
1.2% |
2.3% |
| Melanoma |
0.1% |
0.0% |
0.1% |
0.0% |
0.1% |
0.0% |
0.0% |
| Breast |
0.4% |
0.4% |
0.4% |
0.2% |
0.9% |
0.1% |
0.2% |
| Cervix |
0.4% |
0.7% |
0.4% |
0.5% |
0.0% |
2.5% |
0.0% |
| Other Female Genitals |
1.1% |
1.0% |
1.1% |
0.4% |
1.7% |
0.2% |
1.6% |
| Prostate |
0.7% |
0.6% |
0.7% |
0.2% |
1.1% |
0.1% |
0.9% |
| Kidney |
1.5% |
1.2% |
1.6% |
1.4% |
1.1% |
0.0% |
2.1% |
| Bladder |
1.5% |
1.0% |
1.6% |
0.6% |
1.4% |
0.0% |
1.6% |
| Brain and CNS |
1.4% |
1.3% |
1.4% |
0.7% |
1.4% |
0.0% |
3.2% |
| Thyroid & other endocrine glands |
0.8% |
1.0% |
0.7% |
1.0% |
0.8% |
1.1% |
1.4% |
| CUP |
8.3% |
8.3% |
8.4% |
5.1% |
14.1% |
5.5% |
8.4% |
| Other invasive cancer |
2.5% |
3.2% |
2.4% |
1.8% |
5.8% |
3.0% |
2.8% |
| Breast in situ |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
| Cervix in situ |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
| Other tumours |
1.0% |
0.6% |
1.3% |
0.2% |
1.5% |
0.1% |
0.0% |
Percentage (%) of microscopically verified cases (persons)
|
UKIACR average (population) |
UKIACR average (country) |
England |
Scotland |
Wales |
Northern Ireland |
Republic of Ireland |
| All invasive xnmsc |
85.4% |
85.8% |
85.4% |
84.2% |
80.4% |
86.7% |
92.1% |
| All xnmsc 0-24 |
92.7% |
89.3% |
94.2% |
97.7% |
86.8% |
94.9% |
72.7% |
| All xnmsc 25-59 |
96.2% |
96.0% |
96.2% |
96.5% |
92.0% |
97.4% |
98.1% |
| All xnmsc 60-79 |
89.2% |
89.1% |
89.3% |
87.7% |
83.8% |
90.3% |
94.7% |
| All xnmsc 80+ |
64.0% |
64.4% |
64.1% |
60.6% |
61.0% |
62.5% |
73.7% |
| All registrations |
90.0% |
88.9% |
90.2% |
89.7% |
78.6% |
90.5% |
95.3% |
| Haematology |
86.7% |
87.6% |
86.2% |
95.6% |
74.9% |
88.9% |
92.4% |
| Head and Neck |
97.2% |
97.0% |
97.3% |
97.0% |
96.1% |
98.3% |
96.1% |
| Lower GI |
89.3% |
90.0% |
89.1% |
88.8% |
84.4% |
93.0% |
94.9% |
| Upper GI |
92.7% |
91.4% |
93.1% |
92.5% |
86.1% |
90.8% |
94.4% |
| HPB |
52.1% |
54.6% |
51.9% |
44.4% |
50.2% |
58.7% |
67.6% |
| Trachea, Bronchus & Lung |
71.0% |
72.6% |
70.8% |
66.3% |
69.5% |
71.0% |
85.5% |
| Melanoma |
99.5% |
99.4% |
99.5% |
100.0% |
97.4% |
100.0% |
99.8% |
| Breast |
98.5% |
98.4% |
98.5% |
98.5% |
96.6% |
99.4% |
99.2% |
| Cervix |
98.1% |
97.2% |
98.4% |
97.6% |
96.7% |
96.3% |
97.0% |
| Other Female Genitals |
94.0% |
92.9% |
94.4% |
92.5% |
89.3% |
95.5% |
92.8% |
| Prostate |
87.1% |
88.6% |
86.4% |
89.0% |
84.5% |
86.4% |
96.6% |
| Kidney |
74.6% |
76.3% |
74.0% |
78.7% |
62.9% |
80.8% |
84.9% |
| Bladder |
90.1% |
89.5% |
90.4% |
88.1% |
85.4% |
89.7% |
93.7% |
| Brain and CNS |
70.8% |
70.1% |
70.8% |
70.6% |
61.5% |
69.3% |
78.4% |
| Thyroid & other endocrine glands |
96.1% |
93.8% |
96.7% |
96.0% |
88.8% |
95.4% |
92.2% |
| CUP |
48.4% |
46.7% |
48.9% |
46.7% |
30.0% |
41.7% |
66.0% |
| Other invasive cancer |
86.4% |
83.6% |
87.7% |
78.7% |
74.6% |
85.0% |
92.0% |
| Breast in situ |
99.9% |
99.5% |
100.0% |
100.0% |
97.9% |
100.0% |
99.8% |
| Cervix in situ |
99.9% |
99.7% |
100.0% |
100.0% |
98.3% |
100.0% |
100.0% |
| Other tumours |
87.4% |
83.0% |
88.7% |
92.9% |
51.2% |
85.7% |
96.5% |
Percentage (%) of non-specificity of morphology codes for cases which are microscopically verified
|
UKIACR average (population) |
UKIACR average (country) |
England |
Scotland |
Wales |
Northern Ireland |
Republic of Ireland |
| All invasive xnmsc |
2.0% |
3.7% |
1.5% |
1.5% |
11.0% |
1.5% |
2.8% |
| All xnmsc 0-24 |
2.6% |
8.4% |
1.0% |
0.7% |
37.6% |
0.9% |
1.9% |
| All xnmsc 25-59 |
1.4% |
2.8% |
0.9% |
0.8% |
9.3% |
0.7% |
2.4% |
| All xnmsc 60-79 |
1.9% |
3.4% |
1.4% |
1.5% |
9.9% |
1.6% |
2.8% |
| All xnmsc 80+ |
3.5% |
5.5% |
2.9% |
2.6% |
15.5% |
2.6% |
4.1% |
| All registrations |
1.5% |
3.1% |
1.1% |
1.1% |
8.7% |
2.7% |
1.7% |
| Haematology |
5.3% |
21.3% |
0.8% |
0.6% |
97.3% |
1.2% |
6.4% |
| Head and Neck |
1.9% |
1.9% |
1.9% |
1.7% |
1.2% |
2.0% |
3.0% |
| Lower GI |
1.0% |
1.2% |
0.9% |
0.4% |
3.0% |
0.5% |
1.2% |
| Upper GI |
1.9% |
2.2% |
1.8% |
1.6% |
3.4% |
1.6% |
2.4% |
| HPB |
6.4% |
7.8% |
5.9% |
6.7% |
15.2% |
5.2% |
6.3% |
| Trachea, Bronchus & Lung |
3.2% |
3.6% |
3.0% |
2.7% |
5.1% |
1.4% |
5.8% |
| Melanoma |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
| Breast |
1.0% |
1.3% |
0.9% |
1.5% |
1.2% |
2.0% |
1.2% |
| Cervix |
1.1% |
1.2% |
1.1% |
0.3% |
1.4% |
1.3% |
2.2% |
| Other Female Genitals |
1.3% |
1.7% |
1.2% |
0.7% |
3.0% |
0.8% |
2.9% |
| Prostate |
0.5% |
0.7% |
0.4% |
0.3% |
2.0% |
0.3% |
0.5% |
| Kidney |
1.3% |
1.8% |
1.2% |
1.7% |
2.0% |
1.5% |
2.7% |
| Bladder |
0.9% |
1.5% |
0.8% |
0.1% |
1.9% |
2.1% |
2.6% |
| Brain and CNS |
0.5% |
0.7% |
0.5% |
0.7% |
1.8% |
0.0% |
0.7% |
| Thyroid & other endocrine glands |
2.4% |
2.2% |
2.4% |
1.0% |
1.8% |
1.2% |
4.6% |
| CUP |
19.4% |
19.9% |
19.5% |
15.8% |
30.6% |
14.7% |
19.1% |
| Other invasive cancer |
1.5% |
2.7% |
1.1% |
0.8% |
3.0% |
3.5% |
5.0% |
| Breast in situ |
0.2% |
0.2% |
0.2% |
0.2% |
0.0% |
0.4% |
0.2% |
| Cervix in situ |
0.1% |
0.2% |
0.1% |
0.0% |
0.5% |
0.0% |
0.2% |
| Other tumours |
3.5% |
6.6% |
2.9% |
2.1% |
16.1% |
12.0% |
0.0% |
Mortality : Incidence ratios
|
UKIACR average (population) |
UKIACR average (country) |
England |
Scotland |
Wales |
Northern Ireland |
Republic of Ireland |
| All invasive xnmsc |
0.45 |
0.46 |
0.45 |
0.51 |
0.46 |
0.46 |
0.42 |
| All xnmsc 0-24 |
0.12 |
0.11 |
0.12 |
0.11 |
0.09 |
0.13 |
0.11 |
| All xnmsc 25-59 |
0.24 |
0.25 |
0.23 |
0.28 |
0.24 |
0.24 |
0.23 |
| All xnmsc 60-79 |
0.42 |
0.44 |
0.42 |
0.49 |
0.43 |
0.45 |
0.41 |
| All xnmsc 80+ |
0.78 |
0.80 |
0.77 |
0.84 |
0.75 |
0.80 |
0.84 |
| All registrations |
0.28 |
0.28 |
0.28 |
0.31 |
0.31 |
0.25 |
0.23 |
| Haematology |
0.41 |
0.44 |
0.40 |
0.48 |
0.40 |
0.49 |
0.42 |
| Head and Neck |
0.32 |
0.35 |
0.31 |
0.35 |
0.30 |
0.38 |
0.38 |
| Lower GI |
0.38 |
0.39 |
0.37 |
0.42 |
0.41 |
0.35 |
0.38 |
| Upper GI |
0.77 |
0.78 |
0.77 |
0.82 |
0.81 |
0.76 |
0.75 |
| HPB |
0.84 |
0.84 |
0.84 |
0.87 |
0.80 |
0.81 |
0.86 |
| Trachea, Bronchus & Lung |
0.77 |
0.78 |
0.76 |
0.81 |
0.77 |
0.78 |
0.79 |
| Melanoma |
0.15 |
0.15 |
0.16 |
0.13 |
0.17 |
0.15 |
0.14 |
| Breast |
0.21 |
0.21 |
0.21 |
0.21 |
0.22 |
0.20 |
0.24 |
| Cervix |
0.28 |
0.31 |
0.26 |
0.31 |
0.40 |
0.22 |
0.35 |
| Other Female Genitals |
0.39 |
0.40 |
0.38 |
0.44 |
0.39 |
0.37 |
0.43 |
| Prostate |
0.24 |
0.24 |
0.25 |
0.32 |
0.22 |
0.23 |
0.16 |
| Kidney |
0.35 |
0.36 |
0.34 |
0.39 |
0.33 |
0.37 |
0.38 |
| Bladder |
0.53 |
0.55 |
0.53 |
0.64 |
0.47 |
0.56 |
0.54 |
| Brain and CNS |
0.77 |
0.80 |
0.75 |
1.00 |
0.77 |
0.77 |
0.73 |
| Thyroid & other endocrine glands |
0.15 |
0.16 |
0.14 |
0.16 |
0.16 |
0.18 |
0.14 |
| CUP |
1.14 |
1.06 |
1.18 |
0.91 |
1.14 |
1.40 |
0.67 |
| Other invasive cancer |
0.78 |
0.76 |
0.78 |
0.83 |
0.75 |
0.88 |
0.54 |
| Breast in situ |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| Cervix in situ |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| Other tumours |
0.07 |
0.05 |
0.09 |
0.04 |
0.07 |
0.03 |
0.00 |
Completeness of the dataset (%) - demographics and diagnostic details
|
UKIACR average (population) |
UKIACR average (country) |
England |
Scotland |
Wales |
Northern Ireland |
Republic of Ireland |
| Patient's name |
100.0% |
100.0% |
100.0% |
100.0% |
100.0% |
100.0% |
100.0% |
| Patient's address |
99.7% |
99.6% |
99.7% |
100.0% |
100.0% |
100.0% |
98.2% |
| Sex |
100.0% |
100.0% |
100.0% |
100.0% |
100.0% |
100.0% |
100.0% |
| Ethnicity |
86.2% |
62.5% |
91.8% |
67.8% |
28.0% |
NA |
NA |
| Date of death (where dead) |
100.0% |
100.0% |
100.0% |
100.0% |
100.0% |
100.0% |
99.9% |
| Postcode |
100.0% |
100.0% |
100.0% |
100.0% |
100.0% |
100.0% |
NA |
| Date of birth |
100.0% |
100.0% |
100.0% |
100.0% |
100.0% |
100.0% |
100.0% |
| Unique health identifier |
99.9% |
100.0% |
99.9% |
100.0% |
100.0% |
99.9% |
NA |
| Anniversary (diagnosis) date |
100.0% |
100.0% |
99.9% |
100.0% |
100.0% |
100.0% |
100.0% |
| Site of primary growth |
97.5% |
97.5% |
97.6% |
97.1% |
97.1% |
98.2% |
97.7% |
| Type of growth |
89.0% |
86.2% |
90.0% |
88.4% |
71.5% |
88.0% |
93.1% |
| Behaviour of growth |
99.9% |
99.9% |
100.0% |
99.7% |
99.7% |
99.9% |
100.0% |
| Basis of diagnosis |
99.2% |
98.8% |
99.4% |
99.9% |
98.9% |
99.2% |
96.8% |
| Diagnosis with hospital |
97.4% |
96.1% |
97.9% |
93.2% |
98.3% |
95.5% |
95.8% |
% of all cancer cases (xnmsc)
|
UKIACR average (population) |
UKIACR average (country) |
England |
Scotland |
Wales |
Northern Ireland |
Republic of Ireland |
| Treatment |
83.3% |
74.0% |
87.5% |
69.8% |
57.3% |
90.6% |
64.8% |
| No Treatment |
6.3% |
11.4% |
2.4% |
29.9% |
NA |
0.2% |
13.0% |
| Stage I and II patients receiving any treatment (%) |
93.2% |
88.0% |
94.6% |
86.8% |
81.3% |
93.1% |
84.3% |
% of Cases treated with Surgery
|
UKIACR average (population) |
UKIACR average (country) |
England |
Scotland |
Wales |
Northern Ireland |
Republic of Ireland |
| All invasive xnmsc |
46.7% |
45.2% |
47.7% |
42.1% |
38.7% |
54.3% |
43.1% |
| All xnmsc 0-24 |
48.5% |
47.7% |
49.2% |
49.4% |
47.3% |
55.1% |
37.4% |
| All xnmsc 25-59 |
63.6% |
61.1% |
64.9% |
60.5% |
54.7% |
69.5% |
56.0% |
| All xnmsc 60-79 |
46.5% |
44.5% |
47.7% |
41.0% |
39.0% |
54.0% |
40.6% |
| All xnmsc 80+ |
28.9% |
27.8% |
29.7% |
23.5% |
22.7% |
35.3% |
27.7% |
| Haematology |
6.0% |
8.4% |
5.3% |
3.8% |
14.1% |
9.2% |
9.7% |
| Head and Neck |
52.0% |
49.6% |
53.5% |
44.2% |
47.9% |
53.6% |
48.7% |
| Lower GI |
65.5% |
66.0% |
66.0% |
64.9% |
56.8% |
82.8% |
59.5% |
| Upper GI |
32.9% |
27.6% |
36.5% |
15.4% |
10.6% |
49.0% |
26.4% |
| HPB |
29.3% |
26.3% |
31.7% |
13.3% |
10.8% |
45.4% |
30.0% |
| Trachea, Bronchus & Lung |
22.2% |
19.7% |
23.8% |
13.1% |
16.1% |
27.7% |
17.9% |
| Melanoma |
92.3% |
90.9% |
92.5% |
98.1% |
85.8% |
89.6% |
88.6% |
| Breast |
75.9% |
74.5% |
76.7% |
76.6% |
70.7% |
84.5% |
64.2% |
| Cervix |
58.6% |
50.9% |
64.2% |
26.9% |
44.0% |
61.7% |
57.4% |
| Other Female Genitals |
72.3% |
68.5% |
73.8% |
69.9% |
57.6% |
74.5% |
66.9% |
| Prostate |
21.5% |
18.6% |
22.3% |
15.8% |
14.3% |
17.8% |
22.9% |
| Kidney |
59.3% |
59.2% |
59.9% |
55.2% |
48.8% |
75.5% |
56.8% |
| Bladder |
81.6% |
75.3% |
84.0% |
77.4% |
77.3% |
87.8% |
50.0% |
| Brain and CNS |
48.3% |
51.7% |
47.1% |
55.1% |
38.1% |
58.4% |
59.6% |
| Thyroid & other endocrine glands |
79.1% |
75.4% |
80.6% |
77.7% |
65.6% |
86.2% |
67.1% |
| CUP |
13.1% |
11.7% |
14.4% |
6.8% |
8.0% |
19.6% |
9.5% |
| Other invasive cancer |
51.1% |
49.1% |
52.4% |
45.4% |
42.0% |
56.8% |
48.7% |
| Breast in situ |
85.0% |
84.4% |
85.5% |
94.2% |
77.1% |
95.8% |
69.4% |
| Cervix in situ |
82.3% |
63.7% |
87.9% |
85.3% |
58.5% |
13.3% |
73.4% |
| Other tumours |
58.8% |
54.4% |
60.4% |
60.9% |
39.4% |
47.6% |
63.3% |
| Non-Melanoma Skin Cancer |
50.7% |
71.1% |
43.1% |
89.5% |
85.3% |
56.4% |
80.9% |
% of Cases treated with Radiotherapy
|
UKIACR average (population) |
UKIACR average (country) |
England |
Scotland |
Wales |
Northern Ireland |
Republic of Ireland |
| All invasive xnmsc |
19.5% |
18.7% |
20.0% |
20.1% |
10.9% |
25.5% |
17.0% |
| All xnmsc 0-24 |
12.9% |
12.1% |
13.5% |
10.0% |
7.3% |
20.3% |
9.1% |
| All xnmsc 25-59 |
22.2% |
21.7% |
22.6% |
24.0% |
13.4% |
29.8% |
18.9% |
| All xnmsc 60-79 |
21.8% |
20.5% |
22.5% |
22.1% |
12.0% |
28.0% |
18.0% |
| All xnmsc 80+ |
11.4% |
10.6% |
11.8% |
10.7% |
6.2% |
13.5% |
10.9% |
| Haematology |
8.7% |
8.0% |
9.1% |
8.2% |
3.6% |
11.7% |
7.5% |
| Head and Neck |
54.8% |
52.2% |
56.6% |
48.7% |
38.5% |
66.6% |
50.4% |
| Lower GI |
12.4% |
11.8% |
12.6% |
11.6% |
8.5% |
13.3% |
13.0% |
| Upper GI |
17.7% |
16.6% |
17.9% |
16.2% |
11.4% |
12.1% |
25.3% |
| HPB |
2.3% |
2.9% |
2.2% |
2.3% |
1.1% |
4.9% |
3.9% |
| Trachea, Bronchus & Lung |
26.8% |
25.7% |
27.1% |
30.1% |
17.6% |
31.9% |
21.7% |
| Melanoma |
0.9% |
1.2% |
0.9% |
0.4% |
1.3% |
2.0% |
1.3% |
| Breast |
35.1% |
33.4% |
36.0% |
38.4% |
14.0% |
50.0% |
28.6% |
| Cervix |
39.6% |
42.7% |
38.1% |
49.1% |
29.3% |
54.3% |
42.6% |
| Other Female Genitals |
14.3% |
15.1% |
14.1% |
15.2% |
14.0% |
18.2% |
13.8% |
| Prostate |
17.1% |
14.5% |
18.5% |
10.7% |
5.8% |
26.0% |
11.3% |
| Kidney |
5.2% |
5.2% |
5.2% |
5.7% |
4.4% |
6.5% |
4.2% |
| Bladder |
15.4% |
14.2% |
15.9% |
14.7% |
11.6% |
19.7% |
9.1% |
| Brain and CNS |
43.2% |
43.9% |
43.1% |
42.2% |
28.1% |
54.7% |
51.5% |
| Thyroid & other endocrine glands |
29.7% |
25.5% |
31.8% |
25.0% |
18.4% |
39.1% |
13.1% |
| CUP |
11.2% |
9.9% |
11.9% |
8.2% |
6.1% |
12.9% |
10.5% |
| Other invasive cancer |
15.2% |
12.3% |
16.3% |
12.5% |
8.4% |
13.5% |
10.8% |
| Breast in situ |
29.5% |
30.7% |
29.1% |
38.6% |
15.2% |
38.0% |
32.8% |
| Cervix in situ |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.1% |
0.1% |
| Other tumours |
1.0% |
1.1% |
1.1% |
0.4% |
0.6% |
2.9% |
0.7% |
| Non-Melanoma Skin Cancer |
1.0% |
1.2% |
1.1% |
0.5% |
1.7% |
1.7% |
0.9% |
% of Cases treated with Teletherapy
|
UKIACR average (population) |
UKIACR average (country) |
England |
Scotland |
Wales |
Northern Ireland |
Republic of Ireland |
| All invasive xnmsc |
17.0% |
19.0% |
16.8% |
NA |
NA |
23.8% |
16.3% |
| All xnmsc 0-24 |
10.0% |
11.3% |
9.9% |
NA |
NA |
15.3% |
8.7% |
| All xnmsc 25-59 |
17.5% |
20.6% |
17.2% |
NA |
NA |
26.6% |
18.0% |
| All xnmsc 60-79 |
19.3% |
21.0% |
19.2% |
NA |
NA |
26.6% |
17.1% |
| All xnmsc 80+ |
11.1% |
11.7% |
11.1% |
NA |
NA |
13.3% |
10.8% |
| Haematology |
8.8% |
9.3% |
8.8% |
NA |
NA |
11.7% |
7.5% |
| Head and Neck |
40.3% |
51.9% |
38.6% |
NA |
NA |
66.6% |
50.4% |
| Lower GI |
7.6% |
11.1% |
7.0% |
NA |
NA |
13.3% |
13.0% |
| Upper GI |
14.5% |
17.1% |
13.8% |
NA |
NA |
12.1% |
25.3% |
| HPB |
1.9% |
3.4% |
1.7% |
NA |
NA |
4.5% |
3.9% |
| Trachea, Bronchus & Lung |
25.5% |
26.4% |
25.5% |
NA |
NA |
31.9% |
21.7% |
| Melanoma |
0.9% |
1.4% |
0.9% |
NA |
NA |
2.0% |
1.2% |
| Breast |
35.5% |
38.0% |
35.6% |
NA |
NA |
50.0% |
28.5% |
| Prostate |
19.0% |
21.1% |
17.5% |
NA |
NA |
6.2% |
39.6% |
| Cervix |
8.7% |
7.8% |
8.8% |
NA |
NA |
6.7% |
7.9% |
| Other Female Genitals |
16.0% |
16.3% |
16.4% |
NA |
NA |
23.4% |
9.3% |
| Kidney |
4.9% |
5.2% |
4.9% |
NA |
NA |
6.5% |
4.2% |
| Bladder |
14.0% |
14.3% |
14.2% |
NA |
NA |
19.7% |
9.1% |
| Brain and CNS |
31.6% |
45.2% |
29.3% |
NA |
NA |
54.7% |
51.5% |
| Thyroid & other endocrine glands |
7.6% |
7.7% |
7.7% |
NA |
NA |
10.3% |
4.9% |
| CUP |
10.5% |
11.3% |
10.4% |
NA |
NA |
12.9% |
10.5% |
| Other invasive cancer |
12.5% |
12.3% |
12.6% |
NA |
NA |
13.5% |
10.7% |
| Breast in situ |
29.5% |
33.3% |
29.0% |
NA |
NA |
38.0% |
32.8% |
| Cervix in situ |
0.0% |
0.1% |
0.0% |
NA |
NA |
0.1% |
0.1% |
| Other tumours |
1.0% |
1.5% |
0.9% |
NA |
NA |
2.9% |
0.7% |
| Non-Melanoma Skin Cancer |
1.0% |
1.2% |
1.0% |
NA |
NA |
1.7% |
0.8% |
% of Cases treated with Chemotherapy
|
UKIACR average (population) |
UKIACR average (country) |
England |
Scotland |
Wales |
Northern Ireland |
Republic of Ireland |
| All invasive xnmsc |
25.8% |
23.7% |
26.5% |
26.2% |
20.3% |
25.7% |
19.8% |
| All xnmsc 0-24 |
56.7% |
48.3% |
60.3% |
60.6% |
51.7% |
55.1% |
14.0% |
| All xnmsc 25-59 |
39.4% |
37.0% |
40.4% |
43.2% |
33.5% |
40.9% |
27.1% |
| All xnmsc 60-79 |
26.4% |
23.7% |
27.3% |
25.8% |
21.1% |
24.5% |
19.6% |
| All xnmsc 80+ |
7.8% |
6.7% |
8.2% |
6.3% |
4.7% |
7.3% |
6.9% |
| Haematology |
51.5% |
46.8% |
52.9% |
58.6% |
34.3% |
52.8% |
35.5% |
| Head and Neck |
28.9% |
25.2% |
30.4% |
25.6% |
28.8% |
24.6% |
16.6% |
| Lower GI |
31.5% |
28.5% |
32.5% |
30.0% |
24.7% |
28.5% |
26.8% |
| Upper GI |
38.8% |
35.7% |
40.4% |
36.6% |
30.5% |
43.3% |
28.0% |
| HPB |
23.6% |
21.3% |
24.7% |
19.9% |
15.8% |
26.5% |
19.5% |
| Trachea, Bronchus & Lung |
28.1% |
24.9% |
29.4% |
23.4% |
24.2% |
24.0% |
23.4% |
| Melanoma |
1.1% |
1.2% |
1.1% |
0.4% |
2.2% |
1.0% |
1.5% |
| Breast |
31.7% |
31.0% |
31.9% |
33.3% |
25.9% |
33.4% |
30.6% |
| Cervix |
34.7% |
35.1% |
34.6% |
43.0% |
26.0% |
49.4% |
22.6% |
| Other Female Genitals |
29.2% |
28.6% |
29.3% |
33.9% |
22.2% |
32.4% |
25.2% |
| Prostate |
3.2% |
3.1% |
3.2% |
5.6% |
3.7% |
2.6% |
0.4% |
| Kidney |
8.4% |
8.0% |
8.6% |
4.0% |
9.7% |
8.0% |
9.9% |
| Bladder |
29.7% |
25.2% |
31.1% |
28.7% |
22.9% |
28.2% |
15.0% |
| Brain and CNS |
27.1% |
23.4% |
28.4% |
33.5% |
11.5% |
29.9% |
13.5% |
| Thyroid & other endocrine glands |
4.7% |
4.6% |
4.8% |
4.7% |
5.6% |
4.6% |
3.5% |
| CUP |
11.8% |
8.7% |
12.9% |
7.7% |
5.3% |
5.5% |
12.0% |
| Other invasive cancer |
28.8% |
24.2% |
30.6% |
25.6% |
21.1% |
26.3% |
17.3% |
| Breast in situ |
1.3% |
1.3% |
1.4% |
0.6% |
0.0% |
3.8% |
0.9% |
| Cervix in situ |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.2% |
0.0% |
| Other tumours |
11.1% |
8.3% |
12.7% |
11.3% |
5.3% |
9.2% |
3.2% |
| Non-Melanoma Skin Cancer |
0.1% |
0.4% |
0.1% |
0.6% |
0.2% |
0.9% |
0.1% |
% of Cases for other treatments
|
UKIACR average (population) |
UKIACR average (country) |
England |
Scotland |
Wales |
Northern Ireland |
Republic of Ireland |
| % of Cases treated with Hormone Therapy |
| All invasive xnmsc |
12.1% |
11.9% |
12.4% |
14.9% |
5.4% |
20.6% |
6.1% |
| Breast |
39.9% |
42.6% |
39.1% |
61.7% |
17.3% |
70.3% |
24.6% |
| Prostate |
43.2% |
38.7% |
45.7% |
52.1% |
20.4% |
60.3% |
14.9% |
| % of Cases treated with Brachytherapy |
| All invasive xnmsc |
0.9% |
1.2% |
0.9% |
NA |
NA |
1.7% |
1.1% |
| Breast |
0.0% |
0.1% |
0.0% |
NA |
NA |
0.0% |
0.2% |
| Prostate |
2.4% |
2.5% |
2.3% |
NA |
NA |
3.0% |
2.2% |
| % of Cases treated with Watch & Wait/Active Monitoring |
| All invasive xnmsc |
8.0% |
5.6% |
8.5% |
NA |
NA |
7.0% |
1.3% |
| Prostate |
24.2% |
17.4% |
25.8% |
NA |
NA |
22.1% |
4.2% |
| % of Cases treated with Palliative Care |
| All invasive xnmsc |
8.0% |
6.1% |
8.5% |
NA |
NA |
8.3% |
1.6% |
Specific cohorts where treatment completeness data is expected (%)
|
UKIACR average (population) |
UKIACR average (country) |
England |
Scotland |
Wales |
Northern Ireland |
Republic of Ireland |
| % of children and young adults (0-24 group) with cancer & underwent any treatment |
91.5% |
86.2% |
93.8% |
92.3% |
79.0% |
95.8% |
69.9% |
| % of men under 60 with prostate cancer & received hormone treatment |
19.7% |
19.6% |
21.3% |
28.6% |
11.6% |
32.0% |
4.4% |
| % of men under 60 with cancer (C00-C97 exc. C44) & received hormone treatment |
3.6% |
3.6% |
3.7% |
4.2% |
1.8% |
6.9% |
1.2% |
| % of women under 60 with breast cancer & received hormone treatment |
25.9% |
31.2% |
24.3% |
46.8% |
8.2% |
57.9% |
18.7% |
| % of all haematological cancer patients who received any treatment |
77.6% |
64.3% |
82.5% |
63.9% |
45.2% |
77.0% |
53.0% |
Quality of treatment data
|
UKIACR average (population) |
UKIACR average (country) |
England |
Scotland |
Wales |
Northern Ireland |
Republic of Ireland |
| Surgery (denominator - all tumours known to be treated with surgery, first recorded surgery for that tumour): |
| Date of surgery known |
100.0% |
100.0% |
100.0% |
100.0% |
100.0% |
100.0% |
100.0% |
| Trust / hospital of surgery known |
99.8% |
99.9% |
99.8% |
100.0% |
100.0% |
100.0% |
99.7% |
| Type of surgery known (OPCS4 code) |
99.8% |
98.2% |
100.0% |
NA |
100.0% |
92.6% |
100.0% |
| Teletherapy (denominator - all tumours known to be treated with teletherapy , first recorded teletherapy treatment for that tumour): |
| Date of teletherapy known |
100.0% |
100.0% |
100.0% |
NA |
NA |
100.0% |
100.0% |
| Trust / hospital of teletherapy known |
99.9% |
100.0% |
99.9% |
NA |
NA |
100.0% |
99.9% |
| Fractions and dose known |
97.3% |
97.3% |
NA |
NA |
NA |
97.3% |
NA |
| Chemotherapy (denominator - all tumours known to be treated with chemotherapy, first recorded chemotherapy treatment for that tumour): |
| Date of chemotherapy known |
100.0% |
100.0% |
99.9% |
100.0% |
100.0% |
100.0% |
100.0% |
| Trust / hospital of chemotherapy known |
99.8% |
99.9% |
99.7% |
100.0% |
100.0% |
100.0% |
99.9% |
| Drug name or regimen known |
75.5% |
66.2% |
NA |
NA |
NA |
33.2% |
99.2% |
| Radiotherapy (denominator - all tumours known to be treated with radiotherapy, take the first recorded radiotherapy event for that tumour): |
| Date of radiotherapy known |
100.0% |
100.0% |
100.0% |
100.0% |
100.0% |
100.0% |
100.0% |
| Trust / hospital of radiotherapy known |
99.9% |
100.0% |
99.9% |
100.0% |
100.0% |
100.0% |
99.9% |
Breast cancer screening completeness (%)
|
UKIACR average (population) |
UKIACR average (country) |
England |
Scotland |
Wales |
Northern Ireland |
Republic of Ireland |
| Breast cancer - % screen detected for ages 50-64 (data 2015) |
37.8% |
43.0% |
36.1% |
51.2% |
23.9% |
49.0% |
54.6% |
| Breast cancer - % screen detected for ages 50-64 (last year, 2014) |
48.0% |
50.7% |
47.1% |
48.1% |
51.5% |
51.4% |
55.2% |
| Breast cancer - % with full screening history for ages 50-64 (data 2015) |
72.8% |
76.9% |
71.0% |
99.9% |
38.8% |
97.1% |
77.9% |
| Breast cancer - % with full screening history for ages 50-64 (last year, 2014) |
89.1% |
91.1% |
88.4% |
99.9% |
87.7% |
98.1% |
81.7% |
Cervical cancer screening completeness (%)
|
UKIACR average (population) |
UKIACR average (country) |
England |
Scotland |
Wales |
Northern Ireland |
Republic of Ireland |
| Cervical cancer - % screen detected for ages 25-60 (data 2015) |
11.6% |
20.0% |
6.8% |
45.3% |
NA |
7.9% |
NA |
| Cervical cancer - % screen detected for ages 25-60 (last year, 2014) |
19.2% |
30.0% |
13.8% |
54.4% |
NA |
21.9% |
NA |
| Cervical cancer - % with full screening history for ages 25-60 (data 2015) |
29.8% |
66.8% |
17.8% |
100.0% |
NA |
82.5% |
NA |
| Cervical cancer - % with full screening history for ages 25-60 (last year, 2014) |
39.6% |
76.0% |
28.5% |
99.7% |
NA |
100.0% |
NA |
Bowel cancer screening completeness (%)
|
UKIACR average (population) |
UKIACR average (country) |
England |
Scotland |
Wales |
Northern Ireland |
Republic of Ireland |
| Bowel cancer - % screen detected for ages 60-69 (data 2015) |
4.3% |
18.4% |
0.0% |
27.4% |
19.1% |
27.0% |
NA |
| Bowel cancer - % screen detected for ages 60-69 (last year, 2014) |
18.8% |
23.7% |
17.0% |
29.7% |
21.2% |
26.9% |
NA |
| Bowel cancer - % with full screening history for ages 60-69 (data 2015) |
15.2% |
65.0% |
0.0% |
99.7% |
63.7% |
96.5% |
NA |
| Bowel cancer - % with full screening history for ages 60-69 (last year, 2014) |
71.9% |
83.5% |
68.1% |
99.9% |
67.1% |
99.0% |
NA |
Completeness of the dataset (%) - stage complete by cancer site groups summary (persons)
|
UKIACR average (population) |
UKIACR average (country) |
England |
Scotland |
Wales |
Northern Ireland |
Republic of Ireland |
| All invasive xnmsc |
76.8% |
69.4% |
80.4% |
60.8% |
65.1% |
82.4% |
58.1% |
| Haematology |
57.1% |
27.5% |
68.6% |
0.0% |
0.0% |
68.9% |
0.0% |
| Head and Neck |
77.5% |
65.8% |
87.7% |
0.0% |
84.1% |
96.1% |
60.9% |
| Lower GI |
86.9% |
81.6% |
89.7% |
73.2% |
81.1% |
92.2% |
71.9% |
| Upper GI |
78.2% |
69.6% |
82.1% |
62.6% |
78.3% |
70.8% |
54.2% |
| HPB |
67.7% |
65.1% |
68.9% |
65.6% |
54.7% |
74.6% |
61.5% |
| Trachea, Bronchus & Lung |
89.6% |
84.2% |
91.5% |
90.3% |
84.9% |
92.2% |
62.3% |
| Melanoma |
88.4% |
79.5% |
93.7% |
40.9% |
78.1% |
97.8% |
86.8% |
| Breast |
90.4% |
84.9% |
92.8% |
84.3% |
76.6% |
95.7% |
75.2% |
| Cervix |
81.4% |
83.4% |
80.6% |
91.8% |
80.7% |
96.3% |
67.7% |
| Other Female Genitals |
82.9% |
74.0% |
86.5% |
70.2% |
69.1% |
81.8% |
62.3% |
| Prostate |
87.0% |
79.9% |
90.1% |
77.9% |
77.2% |
91.4% |
63.0% |
| Bladder |
81.3% |
70.9% |
86.1% |
53.9% |
64.8% |
89.2% |
60.5% |
| Kidney |
82.9% |
77.4% |
85.6% |
65.4% |
72.4% |
91.4% |
72.1% |
| Thyroid and other endocrine glands |
65.6% |
64.8% |
69.6% |
0.0% |
86.2% |
98.8% |
69.6% |
| Other invasive cancer |
56.4% |
46.6% |
61.3% |
19.0% |
35.3% |
70.3% |
47.1% |
| Non-Melanoma Skin Cancer |
6.5% |
8.5% |
6.8% |
0.0% |
13.6% |
20.0% |
2.0% |
Completeness of the dataset (%) - grade complete by cancer site groups summary (persons)
|
UKIACR average (population) |
UKIACR average (country) |
England |
Scotland |
Wales |
Northern Ireland |
Republic of Ireland |
| All invasive xnmsc |
58.9% |
55.1% |
60.3% |
58.5% |
40.3% |
61.0% |
55.2% |
| All xnmsc 0-24 |
29.9% |
26.8% |
30.8% |
39.3% |
9.3% |
31.4% |
23.1% |
| All xnmsc 25-59 |
65.9% |
61.9% |
67.4% |
67.0% |
48.7% |
68.7% |
58.0% |
| All xnmsc 60-79 |
63.2% |
58.7% |
64.9% |
62.7% |
42.0% |
65.5% |
58.4% |
| All xnmsc 80+ |
42.2% |
38.9% |
43.4% |
38.6% |
29.7% |
40.8% |
41.9% |
| All registrations |
45.2% |
41.5% |
45.8% |
NA |
NA |
NA |
37.2% |
| Haematology |
15.8% |
21.5% |
13.9% |
41.2% |
1.3% |
10.1% |
40.8% |
| Head and Neck |
79.9% |
75.3% |
81.4% |
83.8% |
66.6% |
82.0% |
62.9% |
| Lower GI |
78.9% |
75.9% |
80.2% |
79.6% |
61.6% |
83.8% |
74.2% |
| Upper GI |
77.2% |
71.5% |
79.3% |
75.4% |
60.7% |
71.3% |
70.9% |
| HPB |
27.7% |
25.8% |
28.6% |
23.0% |
16.0% |
27.8% |
33.5% |
| Trachea, Bronchus & Lung |
28.7% |
27.6% |
29.4% |
26.8% |
20.3% |
32.1% |
29.4% |
| Melanoma |
1.0% |
0.7% |
1.1% |
0.1% |
0.6% |
0.0% |
1.9% |
| Breast |
94.1% |
89.4% |
96.0% |
88.4% |
87.7% |
94.6% |
80.0% |
| Cervix |
79.3% |
73.7% |
82.0% |
80.5% |
82.0% |
76.5% |
47.7% |
| Other Female Genitals |
75.0% |
71.9% |
76.2% |
74.4% |
64.4% |
81.6% |
62.9% |
| Prostate |
79.9% |
71.0% |
83.0% |
86.6% |
26.8% |
82.8% |
75.9% |
| Bladder |
84.7% |
77.0% |
87.4% |
83.6% |
65.0% |
88.7% |
60.5% |
| Kidney |
59.5% |
52.1% |
61.8% |
61.5% |
12.1% |
71.7% |
53.4% |
| Brain and CNS |
68.4% |
64.1% |
70.3% |
69.0% |
14.4% |
91.2% |
75.5% |
| Thyroid and other endocrine glands |
18.7% |
15.4% |
20.0% |
9.7% |
21.1% |
15.0% |
11.3% |
| CUP |
22.4% |
19.0% |
23.3% |
21.9% |
9.7% |
13.5% |
26.7% |
| Other invasive cancer |
30.4% |
27.2% |
31.6% |
30.9% |
10.4% |
38.9% |
24.2% |
| Other tumours |
41.8% |
28.5% |
44.0% |
NA |
NA |
12.9% |
NA |
| Non-Melanoma Skin Cancer |
17.5% |
19.8% |
16.3% |
26.1% |
31.2% |
3.7% |
21.8% |
The performance indicators measure registry performance for the five registries of the United Kingdom & Ireland Association of Cancer Registries:
- National Cancer Registry Ireland
- Northern Ireland Cancer Registry
- Public Health England
- Scottish Cancer Registry
- Welsh Cancer Intelligence & Surveillance Unit
A detailed commentary of the findings for each registry may be found at this link.
An Excel download of the complete results tables may be found at this link.
Printer-friendly version
